Welcome to the Bhargava Laboratory
Understanding the pathophysiology of Multiple Sclerosis to identify new treatment strategies
Metabolomics in MS
There is a major unmet need for biomarkers of MS disease progression. Our lab is currently focusing on the utility of new “omics” technologies such as metabolomics and lipidomics in identifying both prognostic and diagnostic biomarkers for MS. Metabolomics and lipidomics refer to the use of mass spectrometry coupled with liquid or gas chromatography to identify levels of multiple metabolites / lipid species in biological matrices such as plasma and CSF. Current projects involve utilizing metabolomics to identify a metabolic signature of MS, identifying metabolic pathways that are related to progression in MS and utilizing metabolomics to understand the mechanism of action of the disease modifying agent dimethyl fumarate. We are also tracking a large cohort of patients longitudinally to determine whether serum lipidomic profiles predict progression of disease over time. These studies could help better understand the pathophysiology of the disease and provide markers for use in the testing of new therapies for progressive MS.
Leptomeningeal inflammation in MS
Leptomeningeal inflammation has been noted in relapsing remitting MS as well as progressive MS and has been associated with a more severe disease course and increased cortical demyelination. B cells are an important component of these meningeal infiltrates and in a subset of MS patients, ectopic lymphoid follicle like structures can be identified in the meninges. Meningeal inflammatory infiltrates in MS patients can now be detected on MRI imaging providing a possible marker of therapeutic response for trials targeting this process. However, the testing of potential therapeutic agents is hampered by the lack of a suitable animal model.
We performed ultra-high field MRI (11.7 T) in mice with relapsing-remitting EAE late in their disease course and identified meningeal contrast enhancement that pathologically corresponds to meningeal inflammation. These meningeal infiltrates are composed primarily of B and T cells and are associated with demyelination and axonal damage in the adjacent cortex. These lesions also persist and accumulate over time providing a potential marker to test the efficacy of therapies targeting meningeal inflammation. We are currently in the process of further defining the effects of meningeal inflammation on the adjacent cortex and testing new therapeutic agents that could impact the various components of the meningeal infiltrates.
CNS cell-derived Extracellular vesicles in MS
Extracellular vesicles (EVs) are produced by all cells in the body and play important physiological and pathological roles in intercellular communication. Since EVs express proteins on their surface derived from their cell of origin, multiple groups have developed strategies to isolate EV subsets enriched for a particular cell of origin. For example, L1-CAM is an adhesion molecule primarily expressed on neurons and L1-CAM+ EVs are highly enriched in neuronal proteins suggesting that this sub-set of EVs is enriched for neuronal origin. Similarly, GLAST has been identified as a potential marker to identify astrocyte-derived EVs. We partnered with colleagues at the National Institutes of Aging to apply this method to people with MS to help identify a new platform for biomarker discovery and understanding MS pathophysiology.
We noted in a study of 61 people with MS and 31 healthy individuals that neuronally-enriched EVs (NEVs) from people with MS has markedly reduced levels of synaptic proteins and AEVs from people with MS had elevated levels of multiple complement components compared to healthy individuals. These were interesting findings since pathological studies have demonstrated significant synaptic loss in MS and recent studies have suggested that synaptic loss is mediated by complement deposition on these synapses leading to removal by microglia. Most remarkably, we also showed in this study that there was as striking inverse correlation between levels of NEV synaptic proteins and a number of AEV complement component levels suggesting that higher astrocyte complement production drives synaptic loss in MS.
We are currently funded by the Myelin Repair Foundation to evaluate longitudinal changes in these NEV and AEV markers in people with MS and to link them with imaging markers of neurodegeneration. We are also funded to assess longitudinal changes in a broad range of biomarkers in EV subsets in a large cohort of controls, people with RRMS and PMS. We plan to use these EV subset-based biomarkers to monitor effects of therapeutic interventions - such as the effect of TUDCA on AEV complement in our ongoing trial of TUDCA in PMS.
Additionally, we are in the process of identifying markers of OPC- and oligodendroglia-derived EVs to interrogate ongoing damage or repair within these cell populations, especially in trials of putative remyelinating agents.
The Fruits of Our Labor
Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition
June 17, 2020
Synaptic and complement markers in extracellular vesicles in multiple sclerosis
Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation
A Collaborative & Diverse Group
Kanak is a research technologist in the Bhargava lab. She is the driving force behind our leptomeningeal inflammation in MS and EV studies. She plans to attend graduate school in the future.
Dr. Larissa Jank
Dr. Jank is a postdoctoral in the Bhargava lab involved in transaltional studies utilizing EV based biomarkers and multiparametric flow cytometry in MS patients.
Andrew runs our clinical metabolomics studies and is also involved in setting up new investigator initiated trials. He is currently applying for medical school.
Dr. Dimitris Ladakis
Dr. Ladakis is a research fellow in the Bahrgava lab. He runs our trial of belimumab and ocrelizumab in MS in addition to other translational metabolomics studies funded by the DoD.
Dr. Pavan Bhargava
Dr. Bhargava is an Associate Professor of Neurology at the Johns Hopkins University School of Medicine. He went to medical school in India at the Christian Medical College (Vellore) and completed his neurology and neuroimmunology training in the US. His goal is to identify new treatments for progressive MS and to help personalize care of people with MS.
Dr. Ajay Kesharwani
Dr. Kesharwani is a fellow in the Bhargava and Kesharwani labs, involved in research on brain-derived EVs.
Dr. Saumitra Sen Singh
Dr. Singh is a post-doctoral fellow in the Bhargava lab focused on functional metabolomics studies.
Latest developments in the Bhargava Lab
Sophia accepted to Graduate school
Sophia will begin her PhD program at UC Denver in teh Fall. Congratulations !! We will miss you.
Research Opportunities at Bhargava Laboratory
October 12, 2020
Research Coordinator/ Research Fellows
We are looking for candidates interested in working in our research group on the clinical side. We are currently beginning two investigator-initiated trials and you would be involved in getting these off the ground and recruiting/ following patients in these trials. Recent grads/ IMG/ FMGs are welcome to apply. Please contact me at firstname.lastname@example.org.
October 15, 2020
We are looking for candidates interested in working in the laboratory on new porojects related to leptomeningeal inflammation in MS or EVs in MS. Prior experience with animal models of disease and in vitro work with neuronal/ glial cells would be a plus. Please contact me at email@example.com.